Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
03/28 BIOGEN : to Present Data at the 13th International Conference on Alzheimer&rsquo..
03/27 BIOGEN : to Report First Quarter 2017 Financial Results on April 25, 2017
03/16 BIOGEN : Appoints Anirvan Ghosh Senior Vice President, Research and Early Develo..
03/01 BIOGEN : Biotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel..
02/28 BIOGEN : to Present at the Cowen & Company 37th Annual Health Care Conference
02/15 BIOGEN : to Present at the 2017 RBC Capital Markets Global Healthcare Conference
02/07 BIOGEN : to Present at the Leerink Partners 6th Annual Global Healthcare Confere..
02/02 BIOGEN INC : Spin off
02/01 BIOGEN : Completes Separation of Global Hemophilia Business, Bioverativ
01/26DJBIOGEN : Profit Skids, Revenue Grows Less Than Expected
More news
Sector news : Biopharmaceuticals
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Biopharmaceuticals
News from SeekingAlpha
03/27 My Favorite Biotech Takeover Play
03/27 Alzheimer's Cure Is Science's Holy Grail - Will Biogen Find It?
03/26 With Healthcare Now Off Trump's Agenda, It's Time To Dive Into The Sector
03/22 Court Victory Benefits Biogen And Its Tecfidera Rival Alike
03/21 Biogen victory makes company more attractive M&A target - RBC
Financials ($)
Sales 2017 11 286 M
EBIT 2017 6 076 M
Net income 2017 4 029 M
Finance 2017 41,4 M
Yield 2017 -
P/E ratio 2017 14,35
P/E ratio 2018 13,00
EV / Sales 2017 5,13x
EV / Sales 2018 4,68x
Capitalization 57 990 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 315 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC2.75%57 990
CSL LIMITED22.50%43 197
GRIFOLS SA19.78%15 139
More Results